No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Established in 1993 and headquartered in Fuzhou, China, China Resources Boya Bio-pharmaceutical Group Co., Ltd. (formerly Boya Bio-pharmaceutical Group Co., Ltd.) is a comprehensive pharmaceutical enterprise operating across China. The company is engaged in the research, development, production, and sale of a diverse portfolio, primarily focusing on blood products, diabetes medications, and various biochemical and chemical pharmaceuticals. Its extensive range of blood-derived products includes human fibrinogen, human albumin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, and freeze-dried intravenous human immunoglobulin. For diabetes management, the company offers metformin hydrochloride (both tablets and enteric-coated versions), pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules. Additionally, it produces specialized injections such as compound osteotide, oxytocin, and heparin sodium, which are utilized across numerous medical fields, including general medicine, hepatitis treatment, gynecology, and immunomodulatory applications.
www.china-boya.comNo one on the platform currently holds 300294.SZ.
No tracked institution reports a position in 300294.SZ as of their last filing.
No one on the platform has traded 300294.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.1% | 5.9% | 9.4% | — | — | — |
| Rev. Growth % | 18.2% | -4.0% | ||||
| Profit Margin % | 5.5% | 13.2% | 16.5% | |||
| Free Cash Flow Margin % | -20.4% | 14.2% | 5.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.9B | -5.3% | $0.60 | $0.53–$0.67 | — | 2 |
| 2027 | $2.0B | +5.9% | $0.68 | $0.60–$0.76 | — | 1 |
| 2028 | $2.1B | +6.4% | $0.81 | $0.77–$0.85 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-22 | $0.39 | $0.04 | -89.2% |
| 2026-04-24 | $0.03 | $0.06 | +99.7% |
| 2026-03-21 | $0.34 | $-0.46 | -235.3% |
| 2025-10-28 | $0.24 | $0.23 | -2.8% |
| 2025-08-22 | $0.24 | $0.16 | -33.3% |
| 2025-04-24 | $0.27 | $0.28 | +3.7% |
| 2025-03-18 | $0.28 | $-0.03 | -110.7% |
| 2024-10-24 | $0.30 | $0.19 | -36.7% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300294.SZChina Resources Boya Bio-pharmaceutical Group Co., Ltd. | $13.96 | +0.14% | $7.0B | — |
| 002287.SZTibet Cheezheng Tibetan Medicine Co., Ltd. | $19.13 | +0.16% | $10.9B | — |
| 300181.SZZhejiang Jolly Pharmaceutical Co.,LTD | $13.11 | -0.38% | $9.1B | — |
| 300841.SZChengdu Kanghua Biological Products Co., Ltd. | $49.27 | +0.59% | $6.4B | — |
| 301207.SZHualan Biological Bacterin Inc. |
| $18.09 |
| +1.06% |
| $10.8B |
| — |
| 600201.SSJinyu Bio-technology Co., Ltd. | $11.60 | -0.77% | $12.9B | — |
| 600866.SSStar Lake Bioscience Co., Inc.Zhaoqing Guangdong | $4.11 | -1.44% | $6.8B | — |
Source: Financial Modeling Prep · peers by sector/industry